How I treat posttransplant lymphoproliferative disorder

2.

Alaggio

R

,

Amador

C

,

Anagnostopoulos

I

, et al.

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms

.

Leukemia

.

2022

;

36

(

7

):

1720

-

1748

.

3.

Finalet Ferreiro

J

,

Morscio

J

,

Dierickx

D

, et al.

EBV-positive and EBV-negative posttransplant diffuse large B cell lymphomas have distinct genomic and transcriptomic features

.

Am J Transplant

.

2016

;

16

(

2

):

414

-

425

.

4.

Luskin

MR

,

Heil

DS

,

Tan

KS

, et al.

The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder

.

Am J Transplant

.

2015

;

15

(

10

):

2665

-

2673

.

5.

Dierickx

D

,

Habermann

TM

.

Post-transplantation lymphoproliferative disorders in adults

.

N Engl J Med

.

2018

;

378

(

6

):

549

-

562

.

6.

Zaffiri

L

,

Chambers

ET

.

Screening and management of PTLD

.

Transplantation

.

Published online 23 Mar 2023

.

https://doi.org/

7.

Luznik

L

,

Pasquini

MC

,

Logan

B

, et al.

Randomized phase III BMT CTN trial of calcineurin inhibitor–free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies

.

J Clin Oncol

.

2022

;

40

(

4

):

356

-

368

.

8.

Hariharan

S

,

Israni

AK

,

Danovitch

G

.

Long-term survival after kidney transplantation

.

N Engl J Med

.

2021

;

385

(

8

):

729

-

743

.

9.

Sampaio

MS

,

Cho

YW

,

Qazi

Y

,

Bunnapradist

S

,

Hutchinson

IV

,

Shah

T

.

Posttransplant malignancies in solid organ adult recipients: an analysis of the US national transplant database

.

Transplantation

.

2012

;

94

(

10

):

990

-

998

.

10.

Tsai

DE

,

Bagley

S

,

Reshef

R

, et al.

The changing face of adult posttransplant lymphoproliferative disorder: changes in histology between 1999 and 2013

.

Am J Hematol

.

2018

;

93

(

7

):

874

-

881

.

11.

Roberts

MB

,

Fishman

JA

.

Immunosuppressive agents and infectious risk in transplantation: managing the "net state of immunosuppression"

.

Clin Infect Dis

.

2021

;

73

(

7

):

e1302

-

e1317

.

12.

Duncan

MD

,

Wilkes

DS

.

Transplant-related immunosuppression: a review of immunosuppression and pulmonary infections

.

Proc Am Thorac Soc

.

2005

;

2

(

5

):

449

-

455

.

13.

Nelson

J

,

Alvey

N

,

Bowman

L

, et al.

Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: endorsed by the American College of Clinical Pharmacy, American Society of Transplantation, and the International Society for Heart and Lung Transplantation

.

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

.

2022

;

42

(

8

):

599

-

633

.

14.

Lucey

MR

,

Terrault

N

,

Ojo

L

, et al.

Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation

.

Liver Transplant

.

2013

;

19

(

1

):

3

-

26

.

15.

Swinnen

LJ

,

LeBlanc

M

,

Grogan

TM

, et al.

Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder

.

Transplantation

.

2008

;

86

(

2

):

215

-

222

.

16.

Reshef

R

,

Vardhanabhuti

S

,

Luskin

MR

, et al.

Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder

.

Am J Transplant

.

2011

;

11

(

2

):

336

-

347

.

17.

Swinnen

LJ

,

Mullen

GM

,

Carr

TJ

,

Costanzo

MR

,

Fisher

RI

.

Aggressive treatment for postcardiac transplant lymphoproliferation

.

Blood

.

1995

;

86

(

9

):

3333

-

3340

.

18.

Knight

JS

,

Tsodikov

A

,

Cibrik

DM

,

Ross

CW

,

Kaminski

MS

,

Blayney

DW

.

Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center

.

J Clin Oncol

.

2009

;

27

(

20

):

3354

-

3362

.

19.

Evens

AM

,

David

KA

,

Helenowski

I

, et al.

Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era

.

J Clin Oncol

.

2010

;

28

(

6

):

1038

-

1046

.

20.

Bishnoi

R

,

Bajwa

R

,

Franke

AJ

, et al.

Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients

.

Exp Hematol Oncol

.

2017

;

6

(

1

):

26

.

21.

Caillard

S

,

Porcher

R

,

Provot

F

, et al.

Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide french registry and the development of a new prognostic score

.

J Clin Oncol

.

2013

;

31

(

10

):

1302

-

1309

.

22.

Ghobrial

IM

,

Habermann

TM

,

Maurer

MJ

, et al.

Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders

.

J Clin Oncol

.

2005

;

23

(

30

):

7574

-

7582

.

23.

Oton

AB

,

Wang

H

,

Leleu

X

, et al.

Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant

.

Leuk Lymphoma

.

2008

;

49

(

9

):

1738

-

1744

.

24.

Elstrom

RL

,

Andreadis

C

,

Aqui

NA

, et al.

Treatment of PTLD with rituximab or chemotherapy

.

Am J Transplant

.

2006

;

6

(

3

):

569

-

576

.

25.

Maecker

B

,

Jack

T

,

Zimmermann

M

, et al.

CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation

.

J Clin Oncol

.

2007

;

25

(

31

):

4902

-

4908

.

26.

Trappe

R

,

Oertel

S

,

Leblond

V

, et al.

Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial

.

Lancet Oncol

.

2012

;

13

(

2

):

196

-

206

.

27.

Trappe

RU

,

Choquet

S

,

Dierickx

D

, et al.

International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trial

.

Am J Transplant

.

2015

;

15

(

4

):

1091

-

1100

.

28.

Trappe

RU

,

Dierickx

D

,

Zimmermann

H

, et al.

Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial

.

J Clin Oncol

.

2017

;

35

(

5

):

536

-

543

.

29.

Sparano

JA

,

Lee

JY

,

Kaplan

LD

, et al.

Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma

.

Blood

.

2010

;

115

(

15

):

3008

-

3016

.

30.

Ford

M

,

Orlando

E

,

Jin

Z

, et al.

Treatment modalities effect on outcome in post-transplant lymphoproliferative disorder [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

3794

-

3795

.

31.

Chaganti

S

,

Maycock

S

,

McIlroy

G

, et al.

Risk-stratified sequential treatment with ibrutinib and rituximab (IR) and IR-CHOP for de-novo post-transplant lymphoproliferative disorder: results of the Tidal trial [abstract]

.

Blood

.

2021

;

138

(

suppl 1

):

2492

.

32.

Vase

MØ

,

Maksten

EF

,

Bendix

K

, et al.

Occurrence and prognostic relevance of CD30 expression in post-transplant lymphoproliferative disorders

.

Leuk Lymphoma

.

2015

;

56

(

6

):

1677

-

1685

.

33.

Pearse

WB

,

Petrich

AM

,

Gordon

LI

, et al.

A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV+ lymphomas

.

Leuk Lymphoma

.

2021

;

62

(

14

):

3493

-

3500

.

34.

Dharnidharka

V

,

Thirumalai

D

,

Jaeger

U

, et al.

Clinical outcomes of solid organ transplant patients with Epstein-Barr virus-driven (EBV +) post-transplant lymphoproliferative disorder (PTLD) who fail rituximab plus chemotherapy: a multinational, retrospective chart review study [abstract]

.

Blood

.

2021

;

138

(

suppl 1

):

2528

.

35.

Bollard

CM

,

Cohen

JI

.

How I treat T-cell chronic active Epstein-Barr virus disease

.

Blood

.

2018

;

131

(

26

):

2899

-

2905

.

36.

Papadopoulos

EB

,

Ladanyi

M

,

Emanuel

D

, et al.

Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation

.

N Engl J Med

.

1994

;

330

(

17

):

1185

-

1191

.

37.

Mackinnon

S

,

Papadopoulos

EB

,

Carabasi

MH

,

Reich

L

,

Collins

NH

,

O'Reilly

RJ

.

Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response?

.

Bone Marrow Transplant

.

1995

;

15

(

4

):

591

-

594

.

38.

Heslop

HE

,

Brenner

MK

,

Rooney

CM

.

Donor T cells to treat EBV-associated lymphoma

.

N Engl J Med

.

1994

;

331

(

10

):

679

-

680

.

39.

Rooney

CM

,

Smith

CA

,

Ng

CY

, et al.

Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

.

Lancet

.

1995

;

345

(

8941

):

9

-

13

.

40.

Heslop

HE

,

Ng

CY

,

Li

C

, et al.

Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes

.

Nat Med

.

1996

;

2

(

5

):

551

-

555

.

41.

Rooney

CM

,

Smith

CA

,

Ng

CY

, et al.

Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients

.

Blood

.

1998

;

92

(

5

):

1549

-

1555

.

42.

Comoli

P

,

Basso

S

,

Zecca

M

, et al.

Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation

.

Am J Transplant

.

2007

;

7

(

6

):

1648

-

1655

.

43.

Haque

T

,

Wilkie

GM

,

Taylor

C

, et al.

Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells

.

Lancet

.

2002

;

360

(

9331

):

436

-

442

.

44.

Haque

T

,

Wilkie

GM

,

Jones

MM

, et al.

Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial

.

Blood

.

2007

;

110

(

4

):

1123

-

1131

.

45.

Mahadeo

KM

,

Baiocchi

RA

,

Beitinjaneh

A

, et al.

New and updated results from a multicenter, open-label, global phase 3 study of tabelecleucel (tab-cel) for epstein-barr virus-positive posttransplant lymphoproliferative disease (EBV+ PTLD) following allogeneic hematopoietic cell (HCT) or solid organ transplant (SOT) after failure of rituximab or rituximab and chemotherapy (ALLELE) [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

10374

-

10376

.

46.

Prockop

S

,

Doubrovina

E

,

Suser

S

, et al.

Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation

.

J Clin Invest

.

2020

;

130

(

2

):

733

-

747

.

47.

Kazi

S

,

Mathur

A

,

Wilkie

G

, et al.

Long-term follow up after third-party viral-specific cytotoxic lymphocytes for immunosuppression- and Epstein-Barr virus-associated lymphoproliferative disease

.

Haematol

.

2019

;

104

(

8

):

e356

-

e359

.

48.

Chiou

FK

,

Beath

SV

,

Wilkie

GM

,

Vickers

MA

,

Morland

B

,

Gupte

GL

.

Cytotoxic T-lymphocyte therapy for post-transplant lymphoproliferative disorder after solid organ transplantation in children

.

Pediatr Transplant

.

2018

;

22

(

2

):

e13133

.

49.

Vickers

MA

,

Wilkie

GM

,

Robinson

N

, et al.

Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease

.

Br J Haematol

.

2014

;

167

(

3

):

402

-

410

.

50.

Gallot

G

,

Vollant

S

,

Saïagh

S

, et al.

T-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons from a phase I/II feasibility and safety study

.

J Immunother

.

2014

;

37

(

3

):

170

-

179

.

51.

Gandhi

MK

,

Wilkie

GM

,

Dua

U

, et al.

Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders

.

Am J Transplant

.

2007

;

7

(

5

):

1293

-

1299

.

52.

Savoldo

B

,

Goss

JA

,

Hammer

MM

, et al.

Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)

.

Blood

.

2006

;

108

(

9

):

2942

-

2949

.

53.

Comoli

P

,

Maccario

R

,

Locatelli

F

, et al.

Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells

.

Am J Transplant

.

2005

;

5

(

6

):

1415

-

1422

.

54.

Haverkos

BM

,

Alpdogan

O

,

Baiocchi

R

, et al.

Nanatinostat (Nstat) and valganciclovir (VGCV) in relapsed/refractory (R/R) Epstein-Barr virus-positive (EBV +) lymphomas: final results from the phase 1b/2 VT3996-201 study [abstract]

.

Blood

.

2021

;

138

(

suppl 1

):

623

.

55.

Amengual

JE

.

Can we use epigenetics to prime chemoresistant lymphomas?

.

Hematology Am Soc Hematol Educ Program

.

2020

;

2020

(

1

):

85

-

94

.

56.

O'Connor

OA

,

Lue

JK

,

Sawas

A

, et al.

Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial

.

Lancet Oncol

.

2018

;

19

(

2

):

257

-

266

.

57.

Pro

B

,

Advani

R

,

Brice

P

, et al.

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study

.

J Clin Oncol

.

2012

;

30

(

18

):

2190

-

2196

.

58.

Younes

A

,

Bartlett

NL

,

Leonard

JP

, et al.

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

.

N Engl J Med

.

2010

;

363

(

19

):

1812

-

1821

.

59.

Oren

D

,

DeFilippis

EM

,

Lotan

D

, et al.

Successful CAR T cell therapy in a heart and kidney transplant recipient with refractory PTLD

.

JACC CardioOncol

.

2022

;

4

(

5

):

713

-

716

.

60.

Trappe

RU

,

Choquet

S

,

Reinke

P

, et al.

Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after upfront chemotherapy: the role of single-agent rituximab

.

Transplantation

.

2007

;

84

(

12

):

1708

-

1712

.

61.

Kaur

S

,

Shah

P

,

Diaz Duque

AE

,

Shah

DP

.

Post-transplant lymphoproliferative disorder after solid organ transplant: from epidemiology to survival outcomes from 2000-2022 [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

1074

-

1075

.

62.

Eyre

TA

,

Caillard

S

,

Finel

H

, et al.

Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT

.

Bone Marrow Transplant

.

2021

;

56

(

9

):

2118

-

2124

.

63.

Westin

J

,

Sehn

LH

.

CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?

.

Blood

.

2022

;

139

(

18

):

2737

-

2746

.

64.

Abramson

JS

,

Solomon

SR

,

Arnason

J

, et al.

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

.

Blood

.

2023

;

141

(

14

):

1675

-

1684

.

65.

Krishnamoorthy

S

,

Ghobadi

A

,

Santos

RD

, et al.

CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder

.

Am J Transplant

.

2021

;

21

(

2

):

809

-

814

.

66.

Portuguese

AJ

,

Gauthier

J

,

Tykodi

SS

, et al.

CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic review

.

Bone Marrow Transplant

.

2023

;

58

(

4

):

353

-

359

.

67.

McKenna

M

,

Epperla

N

,

Ghobadi

A

, et al.

Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD

.

Br J Haematol

.

2023

;

202

(

2

):

248

-

255

.

68.

Melilli

E

,

Mussetti

A

,

Linares

GS

, et al.

Acute kidney injury following chimeric antigen receptor T-cell therapy for B-cell lymphoma in a kidney transplant recipient

.

Kidney Med

.

2021

;

3

(

4

):

665

-

668

.

69.

Mamlouk

O

,

Nair

R

,

Iyer

SP

, et al.

Safety of CAR T-cell therapy in kidney transplant recipients

.

Blood

.

2021

;

137

(

18

):

2558

-

2562

.

70.

de Nattes

T

,

Camus

V

,

François

A

, et al.

Kidney transplant T cell–mediated rejection occurring after anti-cd19 car t-cell therapy for refractory aggressive Burkitt-like lymphoma with 11q aberration: a case report

.

Am J Kidney Dis

.

2022

;

79

(

5

):

760

-

764

.

71.

Rentsch

V

,

Seipel

K

,

Banz

Y

, et al.

Glofitamab treatment in relapsed or refractory DLBCL after CAR T-cell therapy

.

Cancers

.

2022

;

14

(

10

):

2516

.

72.

Evens

AM

,

Choquet

S

,

Kroll-Desrosiers

AR

, et al.

Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era

.

Am J Transplant

.

2013

;

13

(

6

):

1512

-

1522

.

73.

Guney

E

,

Lucas

CHG

,

Singh

K

, et al.

Molecular profiling identifies at least 3 distinct types of post-transplant lymphoproliferative disorder involving CNS

.

Blood Adv

.

2023

;

7

(

13

):

3307

-

3311

.

74.

Morscio

J

,

Dierickx

D

,

Nijs

J

, et al.

Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases

.

Am J Surg Pathol

.

2014

;

38

(

7

):

875

-

886

.

75.

Karuturi

M

,

Shah

N

,

Frank

D

, et al.

Plasmacytic post-transplant lymphoproliferative disorder: a case series of nine patients

.

Transpl Int

.

2013

;

26

(

6

):

616

-

622

.

76.

Leeman-Neill

RJ

,

Soderquist

CR

,

Montanari

F

, et al.

Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas

.

Haematologica

.

2022

;

107

(

1

):

201

-

210

.

77.

Dumbrava

M

,

Galardy

P

,

Feldman

AL

, et al.

An effective combination therapy for the treatment of pediatric monomorphic post-transplant lymphoproliferative disorder with plasmacytic differentiation

.

J Pediatr Hematol Oncol

.

2023

;

45

(

5

):

e624

-

e627

.

78.

Dittus

C

,

Grover

N

,

Ellsworth

S

,

Tan

X

,

Park

SI

.

Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis

.

Leuk Lymphoma

.

2018

;

59

(

9

):

2121

-

2127

.

79.

Ryu

YK

,

Ricker

EC

,

Soderquist

CR

,

Francescone

MA

,

Lipsky

AH

,

Amengual

JE

.

Targeting CD38 with daratumumab plus chemotherapy for patients with advanced-stage plasmablastoid large B-cell lymphoma

.

J Clin Med

.

2022

;

11

(

16

):

4928

.

80.

Herreman

A

,

Dierickx

D

,

Morscio

J

, et al.

Clinicopathological characteristics of posttransplant lymphoproliferative disorders of T-cell origin: single-center series of nine cases and meta-analysis of 147 reported cases

.

Leuk Lymphoma

.

2013

;

54

(

10

):

2190

-

2199

.

81.

Margolskee

E

,

Jobanputra

V

,

Jain

P

, et al.

Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders

.

Oncotarget

.

2016

;

7

(

25

):

37636

-

37648

.

82.

Rosenberg

AS

,

Klein

AK

,

Ruthazer

R

,

Evens

AM

.

Hodgkin lymphoma post-transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survival

.

Am J Hematol

.

2016

;

91

(

6

):

560

-

565

.

83.

Portuguese

AJ

,

Tykodi

SS

,

Blosser

CD

,

Gooley

TA

,

Thompson

JA

,

Hall

ET

.

Immune checkpoint inhibitor use in solid organ transplant recipients: a systematic review

.

J Natl Compr Canc Netw

.

2022

;

20

(

4

):

406

-

416.e11

.

84.

Schroers-Martin

J

,

Garofalo

A

,

Soo

J

, et al.

Tumor microenvironment determinants of immunotherapy response identified by integrated host & viral analysis of post-transplant lymphoproliferative disorders [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

172

-

174

.